Alessia Chiorazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4056613/publications.pdf

Version: 2024-02-01

47 papers

1,304 citations

331259 21 h-index 35 g-index

47 all docs

47 docs citations

47 times ranked

1841 citing authors

#	Article	IF	CITATIONS
1	Genetic factors influencing the development of vincristine-induced neurotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 215-226.	1.5	14
2	Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity. International Journal of Molecular Sciences, 2021, 22, 1058.	1.8	11
3	Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function. Brain Sciences, 2021, 11, 139.	1.1	6
4	Translating morphology from bench side to bed side via neurophysiology: 8-min protocol for peripheral neuropathy research. Journal of Neuroscience Methods, 2021, 363, 109323.	1.3	8
5	Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers, 2021, 13, 5013.	1.7	6
6	Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. Frontiers in Pharmacology, 2021, 12, 817236.	1.6	6
7	Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors. Pain, 2020, 161, 405-415.	2.0	26
8	Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity Neuropharmacology, 2020, 164, 107905.	2.0	30
9	Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity. Antioxidants, 2020, 9, 594.	2.2	18
10	The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity. Experimental Neurology, 2020, 334, 113458.	2.0	10
11	Reply to a Comment Paper on the Published Paper by Canta, A. et al: "Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicityâ€â€"Antioxidants 2020, 9, 594. Antioxidants, 2020, 9, 807.	2.2	1
12	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Archives of Toxicology, 2020, 94, 2517-2522.	1.9	43
13	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Journal of Clinical Investigation, 2020, 130, 4601-4606.	3.9	44
14	An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. Archives of Toxicology, 2019, 93, 2835-2848.	1.9	16
15	Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer. Frontiers in Pharmacology, 2019, 10, 490.	1.6	14
16	Global Transcriptomic Profile of Dorsal Root Ganglion and Physiological Correlates of Cisplatin-Induced Peripheral Neuropathy. Nursing Research, 2019, 68, 145-155.	0.8	10
17	Artificial apolipoprotein corona enables nanoparticle brain targeting. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 429-438.	1.7	63
18	Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models. European Journal of Pharmacology, 2018, 840, 89-103.	1.7	15

#	Article	IF	Citations
19	Oxaliplatin induces pH acidification in dorsal root ganglia neurons. Scientific Reports, 2018, 8, 15084.	1.6	16
20	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Experimental Neurology, 2018, 307, 129-132.	2.0	51
21	High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. Journal of Neuroinflammation, 2018, 15, 232.	3.1	39
22	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal of Clinical Investigation, 2018, 128, 816-825.	3.9	57
23	Executive control in schizophrenia: a preliminary study on the moderating role of <i>COMT</i> Val158Met for comorbid alcohol and substance use disorders. Nordic Journal of Psychiatry, 2017, 71, 332-339.	0.7	5
24	Facial emotion recognition in schizophrenia: An exploratory study on the role of comorbid alcohol and substance use disorders and <scp>COMT V</scp> al158 <scp>M</scp> et. Human Psychopharmacology, 2017, 32, e2630.	0.7	8
25	Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. Experimental Neurology, 2017, 288, 75-84.	2.0	21
26	Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. PLoS ONE, 2017, 12, e0186250.	1.1	52
27	Age-related changes in the function and structure of the peripheral sensory pathway in mice. Neurobiology of Aging, 2016, 45, 136-148.	1.5	30
28	Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity. Toxics, 2015, 3, 304-321.	1.6	44
29	Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats. Diabetes, 2015, 64, 1035-1045.	0.3	69
30	Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models. Experimental Neurology, 2015, 264, 92-102.	2.0	23
31	Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle, 2014, 13, 612-621.	1.3	62
32	Islet Transplantation and Insulin Administration Relieve Long-Term Complications and Rescue the Residual Endogenous Pancreatic \hat{l}^2 Cells. American Journal of Pathology, 2013, 183, 1527-1538.	1.9	8
33	Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse. PLoS ONE, 2013, 8, e72995.	1.1	69
34	Antibody against tumor necrosis factor- \hat{l}_{\pm} reduces bortezomib-induced allodynia in a rat model. Anticancer Research, 2013, 33, 5453-9.	0.5	20
35	CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. Journal of Pain Research, 2012, 5, 151.	0.8	38
36	Exposure–Response Relationship of the Synthetic Epothilone Sagopilone in a Peripheral Neurotoxicity Rat Model. Neurotoxicity Research, 2012, 22, 91-101.	1.3	2

#	Article	IF	CITATIONS
37	Abstract 933: Peripheral neuropathy induced by chronic administration of Cisplatin, taxol and bortezomib in several murine models. , 2012, , .		O
38	Abstract 5679: Characterization in vivoof two different molecular mechanisms involved in the development of bortezomib-induced peripheral neuropathy. , 2012, , .		O
39	Abstract 657: The new analgesic CR4056 effectively abrogates neuropathic pain induced by Bortezomib in rats., 2011,,.		O
40	Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat. Neurotoxicity Research, 2010, 17, 380-391.	1.3	59
41	Different effects of erythropoietin in cisplatin―and docetaxelâ€induced neurotoxicity: An in vitro study. Journal of Neuroscience Research, 2010, 88, 3171-3179.	1.3	20
42	Bortezomibâ€induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats. European Journal of Pain, 2010, 14, 343-350.	1.4	88
43	The ventral caudal nerve: a physiologicâ€morphometric study in three different rat strains. Journal of the Peripheral Nervous System, 2010, 15, 140-146.	1.4	10
44	Tubulin: A Target for Antineoplastic Drugs into the Cancer Cells but also in the Peripheral Nervous System. Current Medicinal Chemistry, 2009, 16, 1315-1324.	1,2	86
45	Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies. Neurobiology of Disease, 2009, 35, 270-277.	2.1	33
46	Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity. European Journal of Cancer, 2009, 45, 656-665.	1.3	35
47	Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats. Journal of Pain, 2009, 10, 961-968.	0.7	18